STOCKS TELEGRAPH

Tag: Nexgel Inc

  • NEXGEL (NXGL) Sees Stock Boost Following Record Revenue Projections

    NEXGEL (NXGL) Sees Stock Boost Following Record Revenue Projections

    Today’s significant increase in the value of NEXGEL, Inc.’s (NASDAQ: NXGL) shares might be ascribed to the company’s pre-announcement of expected record sales. According to the most recent market data, NXGL shares are now trading at $2.73, up 13.75%. This increase is a result of market confidence after preliminary, unaudited revenue forecasts were disclosed.

    Outstanding Year-Over-Year Increase

    NEXGEL (NXGL) expects to generate around $2.85 million in sales during the third quarter of 2024. This number represents a significant growth of around 98% from quarter to quarter and roughly 133% from year to year.

    Additionally, this predicted revenue is a 30% higher adjustment from the company’s previously released projection of $2.20 million. Based on these anticipated outcomes, NEXGEL is poised to achieve yet another quarter of record breaking earnings, exceeding internal projections in both its contract manufacturing and branded consumer products sectors.

    Strong Performance in Consumer Products

    The growth in NEXGEL’s branded consumer products is noteworthy, particularly in its beauty brand, Silly George. Sales across all three brands have demonstrated significant improvement both year-over-year and quarter-over-quarter.

    Additionally, the company’s contract manufacturing segment has returned to more normalized revenue levels following strategic expansion initiatives, which included an increase in operational space and the installation of advanced automated machinery and clean room facilities.

    Strategic Leadership Expansion

    In conjunction with its revenue growth, NEXGEL has strengthened its leadership by appointing Kip Crecca to its Scientific Advisory Board. With over two decades of experience in medical device sales and management, Mr. Crecca’s expertise is expected to be invaluable as NEXGEL advances its medical device and healthcare programs.

    Currently serving as the Vice President of North America Sales at MicroSurgical Technology, he has held various sales leadership roles at several prominent companies. This appointment aligns with NEXGEL’s commitment to fostering innovation and growth in its healthcare initiatives, ultimately enhancing patient outcomes through advanced hydrogel solutions.

  • Nexgel (NXGL) Sees Recovery On US Stock Charts Following Record Quarterly Revenue

    Nexgel (NXGL) Sees Recovery On US Stock Charts Following Record Quarterly Revenue

    Shares of Nexgel, Inc. (NASDAQ: NXGL) experienced a notable recovery on the US stock charts following the market close on Monday, driven by record revenue figures. During the after-market session, NXGL stock surged by 17.16% to reach $2.39, recovering from a regular-session loss of -7.69%.

    Quarterly Revenue of

    Nexgel

    Nexgel announced its preliminary, unaudited revenue for the second quarter of 2024 and provided revenue guidance for the third and fourth quarters of the same year. According to the preliminary data, Nexgel reported a second-quarter revenue of $1.4 million, marking an approximate 20% increase year-over-year and a 10% sequential growth.

    The company also anticipates a significant year-over-year increase of 83% in Q3 2024, projecting revenues of $2.2 million. Nexgel anticipates growth in the second half of this year, which puts the firm in a strong position to transition to positive cash flow from operations, even if the Q3 estimate does not yet include any revenue from its collaboration with AbbVie.

    Future Outlook

    Despite facing lower-than-normal revenues at CG Converting and Packaging due to a move into a newly expanded facility, Nexgel delivered record revenue for the second quarter of 2024. The company provided an optimistic outlook for the second half of the year, surpassing expectations for both contract manufacturing and consumer products. The growth in contract manufacturing is attributed primarily to new customer relationships with large global corporations, while several NXGL brands are also experiencing substantial growth.

    Strategic Partnership with Cintas Corporation

    In a strategic business move, Nexgel announced a supply agreement with Cintas Corporation, a leading provider of corporate identity uniforms, first aid and safety products, and services to over one million businesses across North America. Through this partnership, Cintas will distribute SilverSeal, a hospital-grade hydrogel dressing for wounds and burns, to its customers across various sectors, including hospitality and public service.

    NXGL expects the first order of SilverSeal to be delivered during the fourth quarter of 2024. This partnership is significant for Nexgel, not only for the associated revenue but also for enhancing brand awareness of SilverSeal.